These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17986340)

  • 1. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial.
    Willeke P; Schlüter B; Becker H; Schotte H; Domschke W; Gaubitz M
    Arthritis Res Ther; 2007; 9(6):R115. PubMed ID: 17986340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of primary sjögren's syndrome-related interstitial lung disease: a retrospective cohort study.
    Amlani B; Elsayed G; Barvalia U; Kanne JP; Meyer KC; Sandbo N; Li Z; McCoy SS
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):136-147. PubMed ID: 33093777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial.
    Nakayamada S; Saito K; Umehara H; Ogawa N; Sumida T; Ito S; Minota S; Nara H; Kondo H; Okada J; Mimori T; Yoshifuji H; Sano H; Hashimoto N; Sugai S; Tanaka Y
    Mod Rheumatol; 2007; 17(6):464-9. PubMed ID: 18084697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
    Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.
    van Woerkom JM; Kruize AA; Geenen R; van Roon EN; Goldschmeding R; Verstappen SM; van Roon JA; Bijlsma JW
    Ann Rheum Dis; 2007 Aug; 66(8):1026-32. PubMed ID: 17223657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
    Dass S; Bowman SJ; Vital EM; Ikeda K; Pease CT; Hamburger J; Richards A; Rauz S; Emery P
    Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Sjögren's syndrome (pSS): subjective symptoms and salivary findings.
    Pedersen AM; Reibel J; Nauntofte B
    J Oral Pathol Med; 1999 Aug; 28(7):303-11. PubMed ID: 10432196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
    Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of Autoimmune Cytopenia to Glandular and Systemic Manifestations in Primary Sjögren Syndrome: Analysis of 113 Korean Patients.
    Koh JH; Lee J; Chung SH; Kwok SK; Park SH
    J Rheumatol; 2015 Oct; 42(10):1817-24. PubMed ID: 26276967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
    Khurshudian AV
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
    Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome.
    Alunno A; Bartoloni E; Valentini V; La Paglia GMC; Valentini E; Leone MC; Marcucci E; Cafaro G; Bonifacio AF; Luccioli F; Gerli R
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):210-214. PubMed ID: 30156545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome.
    Verstappen GM; Kroese FG; Meiners PM; Corneth OB; Huitema MG; Haacke EA; van der Vegt B; Arends S; Vissink A; Bootsma H; Abdulahad WH
    J Rheumatol; 2017 Jan; 44(1):49-58. PubMed ID: 28042126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: a pilot study.
    Adler S; Körner M; Förger F; Huscher D; Caversaccio MD; Villiger PM
    Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1862-8. PubMed ID: 23740889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
    Shao Q; Wang S; Jiang H; Liu L
    Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
    [No Abstract]   [Full Text] [Related]  

  • 18. Sjögren's syndrome with ANCA-associated crescentic extramembranous glomerulonephritis.
    Guillot X; Solau-Gervais E; Coulon A; Debiais F
    Joint Bone Spine; 2009 Mar; 76(2):188-9. PubMed ID: 19196532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between systemic activity ındex and dry eye severity in patients with primary Sjögren syndrome.
    Ozek D; Kemer OE; Omma A
    Arq Bras Oftalmol; 2019; 82(1):45-50. PubMed ID: 30403265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
    Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.